Monthly Prescribing Reference: ‘MK3’ Fixed-Dose Combination Effective in HCV GT 1, 2, and 3
November 2, 2016
A fixed-dose combination of pangenotypic direct-acting antivirals was “‘highly effective” in treatment-native patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3, a study presented at The Liver Meeting (R) 2016 has shown. Read the full story at Monthly Prescribing Reference